2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P3899A
    [Nle8] Somatostatin (1-28) TFA 99.86%
    [Nle8] Somatostatin (1-28) TFA is a derivative of somatosttin (1-28) with norleucine replacing methionine in position 8. [Nle8] Somatostatin (1-28) TFA increases the amylase release.[Nle8] Somatostatin (1-28) TFA increases the cyclic AMP in pancreatic acini .
    [Nle8] Somatostatin (1-28) TFA
  • HY-P4116A
    pH-Low Insertion Peptide TFA
    pH-Low Insertion Peptide TFA (pHLIP TFA) is a short, pH-responsive peptide capable of inserting across a cell membrane to form a transmembrane helix at acidic pH. pH-Low Insertion Peptide TFA targets the acidic tumor microenvironment for tumors at early and metastatic stages with high specificity, used as a specific ligand. pH-Low Insertion Peptide TFA successfully modifys polylysine polymers to have the pH-responsive capability. pH-Low Insertion Peptide TFA -based targeting of cancer presents an opportunity to monitor metabolic changes and to selectively deliver imaging and therapeutic agents to tumors.
    pH-Low Insertion Peptide TFA
  • HY-P4633A
    D-γ-Glu-Tyr 2417507-97-0 99.70%
    D-γ-Glu-Tyr is a D-isomer of γ-Glu-Tyr (HY-P4633), the difference being the γ-Glu content.γ-Glu-Tyr, a competitive inhibitor of dipeptidyl peptidase-IV (DPP-IV) (IC50=6.77 mM), is a potentially functional component of the type 2 diabetes diet.
    D-γ-Glu-Tyr
  • HY-P4794A
    Osteoblast-Adhesive Peptide acetate 98%
    Osteoblast-Adhesive Peptide (Lys-Arg-Ser-Arg) acetate is an adhesion peptide that can be used as a dental/orthopedic biomaterial to support and enhance osteoblast (anchorage-dependent cell) adhesion. Osteoblasts adhere via both integrin-mediated and proteoglycan-mediated mechanisms. Osteoblast-Adhesive Peptide acetate may be osteoblast- or osteocyte-specific and participate in proteoglycan-mediated osteoblast adhesion.
    Osteoblast-Adhesive Peptide acetate
  • HY-P4890A
    Relaxin H3 (human) TFA
    Relaxin H3 (human) TFA is a relaxin peptide with anti-inflammatory, anti-apoptotic, anti-pyroptotic, anti-migratory, protective and anti-fibrotic activities. Relaxin H3 (human) TFA acts on RXFP1 to generate cAMP and reduce the levels of ATP and ROS. Relaxin H3 (human) TFA inhibits renal inflammatory pyroptosis (pyroptosis), NLRP3 inflammasome activation, caspase-1 activation, IL-1β/IL-18 secretion, collagen synthesis, TGF-β1 signaling pathway, Smad2 phosphorylation, myofibroblast differentiation, TIMP expression, and HRMEC migration. Relaxin H3 (human) TFA activates AMPK, upregulates MFN2 expression, improves mitochondrial quality control and membrane potential, inhibits apoptosis (apoptosis) and pyroptosis, restores retinal ultrastructure, and reverses excessive left ventricular collagen expression. Relaxin H3 (human) TFA can be used in studies related to kidney stones, nephrocalcinosis, diabetic cardiomyopathy, fibrotic cardiomyopathy, and diabetic retinopathy.
    Relaxin H3 (human) TFA
  • HY-P5247A
    Palmitoyl tetrapeptide-20 TFA 98%
    Palmitoyl tetrapeptide-20 (PTP20) TFA is a biomimetic peptide agonist of α-MSH. Palmitoyl tetrapeptide-20 TFA promotes hair pigmentation and delays hair graying by activating the MC1-R pathway (AC50: 0.16 nM), enhancing catalase activity to reduce H2O2 accumulation, and upregulating SIRT1 activity. Palmitoyl tetrapeptide-20 TFA can be used in research on preventing hair loss and improving hair graying.
    Palmitoyl tetrapeptide-20 TFA
  • HY-P5305A
    GAD65(247-266) epitope TFA
    GAD65(247-266) epitope TFA is the T cell epitopes of islet antigens，binding to I-Ag7 (type I diabetes-associated molecule) competitively with poor affinity. GAD65 refers to Glutamic Acid Decarboxylase 65，involved in the conversion of glutamate to gamma-aminobutyric acid (GABA).
    GAD65(247-266) epitope TFA
  • HY-P99469
    Bentracimab 2260568-31-6 99.0%
    Bentracimab (PB 2452) is a neutralizing monoclonal antibody that binds Ticagrelor (HY-1006) and its major active circulating metabolite with high affinity. Bentracimab can rapidly reverse the antiplatelet effect of Ticagrelor.
    Bentracimab
  • HY-P99769
    Omfiloctocog alfa 2249927-58-8
    Omfiloctocog alfa (SCT-800) is a recombinant factor VIII (FVIII). FVIII is an essential blood coagulation protein and a key component of the fluid phase blood coagulation system. Omfiloctocog alfa can be used for the research of Hemophilia A.
    Omfiloctocog alfa
  • HY-Q40876
    BBT 445000-45-3 99.71%
    BBT is an enhancer of impaired glucose-stimulated insulin secretion (GSIS). BBT exhibits anti-hyperglycemia activity, and protects β-cells from cytokine- or streptozotocin (STZ (HY-13753))-induced cell death in type 2 diabetes models. BBT acts function via cAMP/PKA and long-lasting (L-type) voltage-dependent Ca2+ channel/CaMK2 pathway.
    BBT
  • HY-Q49697
    Sirtuin modulator 3 708995-11-3 99.32%
    Sirtuin modulator 3 (compound 129) is a N-phenyl benzamide derivative, acts as a sirtuin modulator.
    Sirtuin modulator 3
  • HY-U00017
    Coumetarol 4366-18-1 98.94%
    Coumetarol (Dicumoxane) is a vitamin K antagonist.
    Coumetarol
  • HY-U00070
    Dirlotapide 481658-94-0 99.86%
    Dirlotapide (CP742033) is a gut-selective inhibitor of microsomal triglyceride transfer protein (MTP) that reliably produces weight loss in obese dogs.
    Dirlotapide
  • HY-U00090
    N-Methylmoranoline 69567-10-8 99.0%
    N-Methylmoranoline (MOR 14) is an α-glucosidase inhibitor.
    N-Methylmoranoline
  • HY-U00165
    Midaglizole hydrochloride 79689-25-1 99.67%
    Midaglizole hydrochloride (DG5128) is a preferential α2-adrenoceptor antagonist. Midaglizole hydrochloride (DG5128) exhibits 7.4 times higher affinity (pKi=6.28) toward α2-adrenoceptor than α1-adrenoceptor.
    Midaglizole hydrochloride
  • HY-U00242
    Indacrinone 56049-88-8 99.89%
    Indacrinone (MK196) is an investigational diuretic which has pronounced saluretic activity in the rat and dog as well as both uricosuric and saluretic activity in the chimpanzee.
    Indacrinone
  • HY-U00292
    AMPK activator 1 1152423-98-7 ≥98.0%
    AMPK activator 1 is an AMPK activator extracted from patent WO2013116491A1, compound No.1-75, has an EC50 of <0.1μM.
    AMPK activator 1
  • HY-U00340
    PPAR agonist 1 539813-69-9 98.39%
    PPAR agonist 1 is an agonist of PPAR α and PPAR γ, used for reducing blood glucose, lipid levels, lowering cholesterol and reducing body weight.
    PPAR agonist 1
  • HY-Y0262S
    Oxalic Acid-d2 2065-73-8 98%
    Oxalic Acid-d2 is the deuterium labeled Oxalic Acid. Oxalic Acid is a strong dicarboxylic acid occurring in many plants and vegetables and can be used as an analytical reagent and general reducing agent.
    Oxalic Acid-d2
  • HY-Y0399S
    L-Norvaline-d5 1202936-50-2 99.9%
    L-Norvaline-d5 is the deuterium labeled L-Norvaline. L-Norvaline is the inhibitor for arginase, that promotes the production of NO, reduces oxidative stress, improves insulin resistance, and exhibits antioxidant and anti-hyperglycemic effects. L-Norvaline can be used in research of Alzheimer’s disease.
    L-Norvaline-d5
Cat. No. Product Name / Synonyms Application Reactivity